# A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough

> **NCT05733533** · PHASE2 · COMPLETED · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 97 (actual)

## Conditions studied

- Refractory Chronic Cough

## Interventions

- **DRUG:** HRS-2261 oral tablet
- **DRUG:** Matching placebo to HRS-2261

## Key facts

- **NCT ID:** NCT05733533
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-09
- **Primary completion:** 2024-03-05
- **Final completion:** 2024-03-05
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05733533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05733533, "A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05733533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*